Somatic point mutations in RUNX1/CBFA2/AML1 are common in high-risk myelodysplastic syndrome, but not in myelofibrosis with myeloid metaplasia.

Steensma DP, Gibbons RJ, Mesa RA, Tefferi A, Higgs DR

Bone marrow expression of vascular endothelial growth factor in myelofibrosis with myeloid metaplasia.

Ho CL, Arora B, Hoyer JD, Wellik LE, Mesa RA, Tefferi A

Peripheral blood CD34 count in myelofibrosis with myeloid metaplasia: a prospective evaluation of prognostic value in 94 patients.

Arora B, Sirhan S, Hoyer JD, Mesa RA, Tefferi A

Bone marrow angiogenesis and its clinical correlates in myelofibrosis with myeloid metaplasia.

Arora B, Ho CL, Hoyer JD, Mesa RA, Tefferi A

Thromboembolism in adults with acute lymphoblastic leukemia during induction with L-asparaginase-containing multi-agent regimens: incidence, risk factors, and possible role of antithrombin.

Elliott MA, Wolf RC, Hook CC, Pruthi RK, Heit JA, Letendre LL, Tefferi A, Kaufmann SH, Mesa RA, Litzow MR

Myelofibrosis with myeloid metaplasia: new developments in pathogenesis and treatment.

Dingli D, Mesa RA, Tefferi A

Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia.

Mesa RA, Elliott MA, Schroeder G, Tefferi A

Neutrophil PRV-1 expression across the chronic myeloproliferative disorders and in secondary or spurious polycythemia.

Tefferi A, Lasho TL, Wolanskyj AP, Mesa RA

Concomitant myelodysplastic syndrome and chronic myeloid leukaemia: treatment outcomes with imatinib mesylate.

Mesa RA, Steensma DP, Hoyer J, Ketterling RP

Nonhepatosplenic extramedullary hematopoiesis: associated diseases, pathology, clinical course, and treatment.

Koch CA, Li CY, Mesa RA, Tefferi A